Literature DB >> 6126344

Human metabolism of [1-methyl-14C]- and [2-14C]caffeine after oral administration.

M M Callahan, R S Robertson, M J Arnaud, A R Branfman, M F McComish, D W Yesair.   

Abstract

Radiolabeled caffeine was administered orally at 5 mg/kg to adult, male volunteers. Blood, saliva, expired CO2, urine, and feces were collected and analyzed for total radiolabeled equivalents, caffeine, and its metabolites. High-performance liquid chromatography (HPLC) was the principal technique used to separate caffeine and the various metabolites with quantitation by liquid-scintillation counting. The half-life of caffeine in both serum and saliva was approximately 3 hr, with the concentration of caffeine in the saliva samples ranging from 65 to 85% of that found in the serum samples. The major metabolites found in serum and saliva were the dimethylxanthines. In the course of separating the urinary metabolites, our HPLC system partially resolved two unidentified polar metabolites arising from radiolabeled caffeine. The major component corresponded to 5-acetylamino-6-amino-3-methyluracil and in our subjects ranged from 7 to 35% of the administered dose. The other principal urinary metabolites were 1-methylxanthine at approximately 18% of the administered dose and 1-methyluric acid at 15%. The fecal samples contained approximately 5% of the dose, mainly as uric acid compounds which retained the 1-methyl group. In this study we accounted for approximately 90% of the administered radiolabeled dose and identified greater than 95% of the urinary radioactivity as specific metabolites.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126344

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

1.  Drug pharmacokinetics and the carbon dioxide breath test.

Authors:  E A Lane; I Parashos
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

2.  The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease.

Authors:  N R Scott; D Stambuk; J Chakraborty; V Marks; M Y Morgan
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

3.  Comparison of the urinary metabolite profile of caffeine in young and elderly males.

Authors:  J Blanchard; S J Sawers; J H Jonkman; D D Tang-Liu
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

Review 4.  International society of sports nutrition position stand: caffeine and exercise performance.

Authors:  Nanci S Guest; Trisha A VanDusseldorp; Michael T Nelson; Jozo Grgic; Brad J Schoenfeld; Nathaniel D M Jenkins; Shawn M Arent; Jose Antonio; Jeffrey R Stout; Eric T Trexler; Abbie E Smith-Ryan; Erica R Goldstein; Douglas S Kalman; Bill I Campbell
Journal:  J Int Soc Sports Nutr       Date:  2021-01-02       Impact factor: 5.150

5.  Maternal caffeine intake and DNA methylation in newborn cord blood.

Authors:  Kristen J Polinski; Alexandra Purdue-Smithe; Sonia L Robinson; Sifang Kathy Zhao; Karen C Schliep; Robert M Silver; Weihua Guan; Enrique F Schisterman; Sunni L Mumford; Edwina H Yeung
Journal:  Am J Clin Nutr       Date:  2022-02-09       Impact factor: 8.472

6.  Comparative pharmacokinetics of caffeine in young and elderly men.

Authors:  J Blanchard; S J Sawers
Journal:  J Pharmacokinet Biopharm       Date:  1983-04

7.  Quantitative assessment of caffeine partial clearances in man.

Authors:  A Lelo; J O Miners; R A Robson; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

8.  Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man.

Authors:  A Lelo; D J Birkett; R A Robson; J O Miners
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

9.  Effect of allopurinol on caffeine disposition in man.

Authors:  D M Grant; B K Tang; M E Campbell; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

Review 10.  The clinical toxicology of caffeine: A review and case study.

Authors:  Cyril Willson
Journal:  Toxicol Rep       Date:  2018-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.